Press release

Business update

Production resumed on the PARC® line

Schedule of marketing authorisation filings[1] confirmed

Dijon, 7 December 2017

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing a portfolio of innovative combined drugs for use in emergency situations, provides a trading update in line with its financial agenda.

Patrick Alexandre, CEO of Crossject, said: *"Since our previous update, production has resumed on our PARC® line (Pret-A-Remplir Crossject or ready-to-fill tubes), allowing Cenexi to start making clinical and validation batches in early 2018. We have also hired some outstanding profiles during this half-year, cementing the structure of our teams, a key factor in our development. On the strength of these achievements, Crossject confirms its provisional schedule of marketing authorisations filings."*

Industrial scale production and development

Following the measures taken to correct anomalies occurring on the PARC® production unit mid-2017, production of sterile glass tubes has resumed and is progressing in line with expectations.

Crossject has begun supplying Cenexi with the first batches of tubes needed to continue the qualification of the production tool.

Cenexi has also completed the transfers to its manufacturing units of drug formulations and associated analytical methods for ZENEO® Sumatriptan and ZENEO® Midazolam. The transfer for ZENEO® Hydrocortisone is underway. These transfers make it possible to manufacture the drug contained in the ZENEO® device.

The aseptic filling line is expected to be qualified in early 2018.

[1] **Authorisation to market a drug issued by the relevant regulatory authorities.**

Crossject has also entered a new stage in the implementation of its industrial process with the insourcing of a pyrotechnic gas generator manufacturing line. This allows the company to secure its supply of this element, which is critical for Zeneo®, in that it generates the pressure allowing the liquid to be injected through the skin without needles.

In view of these achievements, Crossject confirms its schedule of marketing authorisation filings in the US and Europe (2019 for Zeneo® Sumatriptan, Zeneo® Midazolam, Zeneo® Adrenaline, Zeneo® Hydrocortisone, Zeneo® Naloxone; 2020 for Zeneo® Methotrexate and Zeneo® Terbutaline).

Continuation of negotiations on licensing agreements and launch of the ZENEO® Midazolam tendering process

In the first half of 2018, Crossject will continue to negotiate a licensing agreement for ZENEO® Sumatriptan in the United States, with a view to optimising the terms on which it is signed.

Crossject also confirms the launch in the coming days of its call for tenders to develop the potential of ZENEO® Midazolam.

The aim of this tender is to find a partner to take charge of marketing this drug in the United States. Signing generally takes place around a year after the launch of the tendering process.

Strengthening of Crossject's teams

In the second half, Crossject has further strengthened its Production, Industrialisation and Quality teams and structured its management by creating new positions including Production Director and Quality Control Manager. The reinforcement of the teams backs up Crossject's development strategy by securing key skills in-house and reducing reliance on service providers.

Next release:

21 March 2018 (after trading): 2017 annual results

Contacts:

Crossject
Patrick Alexandre
info@crossject.com

Investor relations
CM-CIC Market Solutions
Catherine Couanau +33 (0)1 53 48 81 97
catherine.couanau@cmcic.fr

Press relations
Buzz & Compagnie
Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com
Audrey Lachat +33 (0)3 80 43 54 89
audrey.lachat@buzzetcompagnie.com

About CROSSJECT · www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ) is a specialty pharma company developing a portfolio of drugs for use in emergency situations (severe migraines, epilepsy, temporary paralysis, anaphylactic shock, overdoses, acute asthma attacks, etc.). With Zeneo®, its patented needle-free injection system, Crossject provides an efficient response to emergencies by enabling the simple self-administration of drugs. Crossject has been listed on the Euronext Growth market since February 2014.

Disclaimer

This press release may contain forward-looking information. This information is based either on trends or objectives, and should not be taken as a forecast of future performance or any other performance indicator. This information is inherently subject to risks and uncertainties, which may in certain cases be beyond the company's control, particularly in the context of an R&D process. A more detailed description of these risks and uncertainties can be found in the company's annual financial report, which is available on its website (www.crossject.com).

Translation for information purposes only. In case of discrepancy between the French and English versions of this press release, only the French version should be deemed valid.